ArticleCureus2026
Tracheal Stent Placement Under Remimazolam Sedation With Preserved Spontaneous Respiration: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anesthetic management for tracheal stent placement is challenging due to a shared airway and risk of hypoxemia. Propofol-based total intravenous anesthesia (TIVA) with preserved spontaneous ventilation is commonly used. Remimazolam, an ultrashort-acting benzodiazepine, may be an alternative; however, clinical experience is limited. A man in his 50s (170 cm in height, weighing 79 kg; BMI 27.3 kg/m²) with critical tracheal compression from an anterior mediastinal tumor underwent rigid bronchoscopy-guided tracheal stent placement. Anesthesia was induced with remimazolam (0.5 mg/kg/hour) and remifentanil (0.25 μg/kg/minute). Transient hypoxemia occurred twice, requiring manual ventilation and temporary interruption. The regimen was adjusted to a 7 mg remimazolam bolus followed by reduced doses (0.2 mg/kg/hour; remifentanil 0.15 μg/kg/minute), providing adequate sedation while preserving spontaneous respiration for most of the 25-minute procedure. The patient awoke promptly after flumazenil and was discharged on day 2. Remimazolam-remifentanil TIVA is feasible, but careful titration is required to avoid respiratory depression and patient movement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.